We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ph2 study

News List

ASLAN presents Ph2 study data for Varlitinib tested on BTC patients biospectrumasia
September 20, 2019
Enrolment in a global pivotal study of varlitinib in second line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in December 2018 and topline data is expected in the second half of 2019.
Abstract on Ph2 study of Varlitinib gets acceptance for oral prentation at CSCP 2019 biospectrumasia
August 28, 2019
New data from Aslan’s study of Varlitinib in patients with advanced or metastatic biliary tract cancer will be presented at upcoming 2019 Chinese Society of Clinical Oncology (CSCO) annual meeting; a largest clinical trial conducted to date on biliary tra